{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T05:01:40Z","timestamp":1783573300772,"version":"3.55.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T00:00:00Z","timestamp":1765929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T00:00:00Z","timestamp":1765929600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["Ricerca Corrente 2025"],"award-info":[{"award-number":["Ricerca Corrente 2025"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-025-07434-x","type":"journal-article","created":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T13:26:27Z","timestamp":1765977987000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["High BRAF variant allele frequency predicts poor outcomes in metastatic melanoma patients treated with BRAF\/MEK inhibitors"],"prefix":"10.1186","volume":"23","author":[{"given":"Michele","family":"Guida","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2414-5549","authenticated-orcid":false,"given":"Benedetta","family":"Apollonio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Romano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Spagnolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Quaglino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Depenni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosamaria","family":"Pinto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Squicciarini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Livia","family":"Fucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piergiorgio","family":"Di Tullio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Chiara","family":"Scaini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Teresa","family":"Maccallini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Indini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Troiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iole","family":"Natalicchio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Brugnara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Lombardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Pellegrini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Queirolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabiana","family":"Perrone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Minisini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Tucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaele","family":"Conca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Costabile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Macr\u00ec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrica","family":"Tanda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Croce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Senetta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Fava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Pugliese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Pellegrini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Melucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele Del","family":"Vecchio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Caraglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Girlando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"De Summa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabino","family":"Strippoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the Italian Melanoma Intergroup (IMI)","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,17]]},"reference":[{"issue":"15","key":"7434_CR1","doi-asserted-by":"publisher","first-page":"2668","DOI":"10.1016\/j.ejca.2014.06.009","volume":"50","author":"AP Barbour","year":"2014","unstructured":"Barbour AP, Tang YH, Armour N, Dutton-Regester K, Krause L, Loffler KA, Lambie D, Burmeister B, Thomas J, Smithers BM, et al. BRAF mutation status is an independent prognostic factor for resected stage IIIB and IIIC melanoma: implications for melanoma staging and adjuvant therapy. Eur J Cancer. 2014;50(15):2668\u201376.","journal-title":"Eur J Cancer"},{"issue":"9","key":"7434_CR2","doi-asserted-by":"publisher","first-page":"e1168","DOI":"10.1111\/jdv.19173","volume":"37","author":"M Claeson","year":"2023","unstructured":"Claeson M, Tan SX, Lambie D, Brown S, Walsh MD, Baade PD, Pandeya N, Whitehead KJ, Soyer HP, Smithers BM, et al. The association between BRAF-V600E mutations and death from thin (=1.00\u00a0mm) melanomas: A nested case-case study from Queensland, Australia<\/at. J Eur Acad Dermatol Venereol. 2023;37(9):e1168\u201372.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"7","key":"7434_CR3","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1056\/NEJMoa1904059","volume":"381","author":"C Robert","year":"2019","unstructured":"Robert C, Grob JJ, Stroyakovskiy D, Karaszewska B, Hauschild A, Levchenko E, Chiarion Sileni V, Schachter J, Garbe C, Bondarenko I, et al. Five-Year outcomes with Dabrafenib plus Trametinib in metastatic melanoma. N Engl J Med. 2019;381(7):626\u201336.","journal-title":"N Engl J Med"},{"issue":"16","key":"7434_CR4","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.2217\/fon-2022-1258","volume":"19","author":"R Dummer","year":"2023","unstructured":"Dummer R, Flaherty KT, Robert C, Arance A, JW BdG, Garbe C, Gogas HJ, Gutzmer R, Krajsova I, Liszkay G, et al. COLUMBUS 5-year update: a randomized, open-label, phase III trial of Encorafenib plus binimetinib versus Vemurafenib or Encorafenib in patients with BRAF. Future Oncol. 2023;19(16):1091\u20138.","journal-title":"Future Oncol"},{"key":"7434_CR5","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.ejca.2022.11.009","volume":"179","author":"J Lee","year":"2023","unstructured":"Lee J, Ahmed T, Maurichi A, Di Guardo L, Stagno AM, Warburton L, Taylor AM, Livingstone E, Rehman S, Khattak A, et al. BRAF inhibitor cessation prior to disease progression in metastatic melanoma: Long-term outcomes. Eur J Cancer. 2023;179:87\u201397.","journal-title":"Eur J Cancer"},{"issue":"16","key":"7434_CR6","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","volume":"381","author":"J Larkin","year":"2019","unstructured":"Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski P, Lao CD, Cowey CL, Schadendorf D, Wagstaff J, Dummer R, et al. Five-Year survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2019;381(16):1535\u201346.","journal-title":"N Engl J Med"},{"key":"7434_CR7","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.ejca.2019.07.010","volume":"119","author":"P Nathan","year":"2019","unstructured":"Nathan P, Ascierto PA, Haanen J, Espinosa E, Demidov L, Garbe C, Guida M, Lorigan P, Chiarion-Sileni V, Gogas H, et al. Safety and efficacy of nivolumab in patients with rare melanoma subtypes who progressed on or after ipilimumab treatment: a single-arm, open-label, phase II study (CheckMate 172). Eur J Cancer. 2019;119:168\u201378.","journal-title":"Eur J Cancer"},{"issue":"23","key":"7434_CR8","doi-asserted-by":"publisher","first-page":"3917","DOI":"10.1200\/JCO.22.02199","volume":"41","author":"R Dummer","year":"2023","unstructured":"Dummer R, Corrie P, Gutzmer R, Meniawy TM, Del Vecchio M, Lebbe C, Guida M, Dutriaux C, Dreno B, Meyer N, et al. First-Line, Fixed-Duration nivolumab plus ipilimumab followed by nivolumab in clinically diverse patient populations with unresectable stage III or IV melanoma: checkmate 401. J Clin Oncol. 2023;41(23):3917\u201329.","journal-title":"J Clin Oncol"},{"issue":"2","key":"7434_CR9","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1200\/JCO.21.02961","volume":"41","author":"PA Ascierto","year":"2023","unstructured":"Ascierto PA, Mandala M, Ferrucci PF, Guidoboni M, Rutkowski P, Ferraresi V, Arance A, Guida M, Maiello E, Gogas H, et al. Sequencing of ipilimumab plus nivolumab and Encorafenib plus binimetinib for untreated BRAF-Mutated metastatic melanoma (SECOMBIT): A Randomized, Three-Arm, Open-Label phase II trial. J Clin Oncol. 2023;41(2):212\u201321.","journal-title":"J Clin Oncol"},{"issue":"1","key":"7434_CR10","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1097\/PPO.0000000000000296","volume":"24","author":"DY Wang","year":"2018","unstructured":"Wang DY, Johnson DB, Davis EJ. Toxicities associated with PD-1\/PD-L1 Blockade. Cancer J. 2018;24(1):36\u201340.","journal-title":"Cancer J"},{"issue":"2","key":"7434_CR11","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1200\/JCO.22.01763","volume":"41","author":"MB Atkins","year":"2023","unstructured":"Atkins MB, Lee SJ, Chmielowski B, Tarhini AA, Cohen GI, Truong TG, Moon HH, Davar D, O\u2019Rourke M, Stephenson JJ, et al. Combination Dabrafenib and Trametinib versus combination nivolumab and ipilimumab for patients with advanced BRAF-Mutant melanoma: the DREAMseq Trial-ECOG-ACRIN EA6134. J Clin Oncol. 2023;41(2):186\u201397.","journal-title":"J Clin Oncol"},{"issue":"1","key":"7434_CR12","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1186\/s12967-023-04391-1","volume":"21","author":"R Dummer","year":"2023","unstructured":"Dummer R, Welti M, Ramelyte E. The role of triple therapy and therapy sequence in treatment of BRAF-mutant metastatic melanoma. Response to overall survival with first-line Atezolizumab in combination with Vemurafenib and Cobimetinib in BRAFV600 mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, randomised, phase 3 study. J Transl Med. 2023;21(1):529.","journal-title":"J Transl Med"},{"issue":"2","key":"7434_CR13","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1200\/JCO.21.02961","volume":"41","author":"PA Ascierto","year":"2023","unstructured":"Ascierto PA, Mandal\u00e0 M, Ferrucci PF, Guidoboni M, Rutkowski P, Ferraresi V, Arance A, Guida M, Maiello E, Gogas H, et al. Sequencing of ipilimumab plus nivolumab and Encorafenib plus binimetinib for untreated. J Clin Oncol. 2023;41(2):212\u201321.","journal-title":"J Clin Oncol"},{"issue":"12","key":"7434_CR14","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1016\/S1470-2045(16)30578-2","volume":"17","author":"GV Long","year":"2016","unstructured":"Long GV, Grob JJ, Nathan P, Ribas A, Robert C, Schadendorf D, Lane SR, Mak C, Legenne P, Flaherty KT, et al. Factors predictive of response, disease progression, and overall survival after Dabrafenib and Trametinib combination treatment: a pooled analysis of individual patient data from randomised trials. Lancet Oncol. 2016;17(12):1743\u201354.","journal-title":"Lancet Oncol"},{"issue":"10","key":"7434_CR15","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1001\/jamaoncol.2018.2668","volume":"4","author":"A Hauschild","year":"2018","unstructured":"Hauschild A, Larkin J, Ribas A, Dreno B, Flaherty KT, Ascierto PA, Lewis KD, McKenna E, Zhu Q, Mun Y, et al. Modeled prognostic subgroups for survival and treatment outcomes in BRAF V600-Mutated metastatic melanoma: pooled analysis of 4 randomized clinical trials. JAMA Oncol. 2018;4(10):1382\u20138.","journal-title":"JAMA Oncol"},{"key":"7434_CR16","doi-asserted-by":"crossref","unstructured":"Soria X, Vilardell F, Maiques O, Barcelo C, Siso P, de la Rosa I, Velasco A, Cuevas D, Santacana M, Gatius S, et al. BRAF(V600E) Mutant Allele Frequency (MAF) influences melanoma clinicopathologic characteristics. Cancers (Basel) : 2021;13(20).","DOI":"10.3390\/cancers13205073"},{"issue":"4","key":"7434_CR17","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1097\/CMR.0000000000000088","volume":"24","author":"C Lebbe","year":"2014","unstructured":"Lebbe C, How-Kit A, Battistella M, Sadoux A, Podgorniak MP, Sidina I, Pages C, Roux J, Porcher R, Tost J, et al. BRAF(V600) mutation levels predict response to Vemurafenib in metastatic melanoma. Melanoma Res. 2014;24(4):415\u20138.","journal-title":"Melanoma Res"},{"issue":"35","key":"7434_CR18","doi-asserted-by":"publisher","first-page":"37895","DOI":"10.18632\/oncotarget.5634","volume":"6","author":"I Satzger","year":"2015","unstructured":"Satzger I, Marks L, Kerick M, Klages S, Berking C, Herbst R, Volker B, Schacht V, Timmermann B, Gutzmer R. Allele frequencies of BRAFV600 mutations in primary melanomas and matched metastases and their relevance for BRAF inhibitor therapy in metastatic melanoma. Oncotarget. 2015;6(35):37895\u2013905.","journal-title":"Oncotarget"},{"issue":"2","key":"7434_CR19","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1111\/pcmr.12569","volume":"30","author":"N Mesbah Ardakani","year":"2017","unstructured":"Mesbah Ardakani N, Leslie C, Grieu-Iacopetta F, Lam WS, Budgeon C, Millward M, Amanuel B. Clinical and therapeutic implications of BRAF mutation heterogeneity in metastatic melanoma. Pigment Cell Melanoma Res. 2017;30(2):233\u201342.","journal-title":"Pigment Cell Melanoma Res"},{"issue":"6","key":"7434_CR20","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1158\/1535-7163.MCT-17-1124","volume":"17","author":"C Stagni","year":"2018","unstructured":"Stagni C, Zamuner C, Elefanti L, Zanin T, Bianco PD, Sommariva A, Fabozzi A, Pigozzo J, Mocellin S, Montesco MC, et al. BRAF gene copy number and mutant allele frequency correlate with time to progression in metastatic melanoma patients treated with MAPK inhibitors. Mol Cancer Ther. 2018;17(6):1332\u201340.","journal-title":"Mol Cancer Ther"},{"issue":"3","key":"7434_CR21","doi-asserted-by":"publisher","first-page":"100133","DOI":"10.1016\/j.esmoop.2021.100133","volume":"6","author":"E Berrino","year":"2021","unstructured":"Berrino E, Balsamo A, Pisacane A, Gallo S, Becco P, Miglio U, Caravelli D, Poletto S, Paruzzo L, Debernardi C, et al. High BRAF variant allele frequencies are associated with distinct pathological features and responsiveness to target therapy in melanoma patients. ESMO Open. 2021;6(3):100133.","journal-title":"ESMO Open"},{"issue":"10","key":"7434_CR22","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.1111\/jdv.19281","volume":"37","author":"M Mandala","year":"2023","unstructured":"Mandala M, Palmieri G, Ludovini V, Baglivo S, Marasciulo F, Castiglione F, Gili A, Osella Abate S, Rubatto M, Senetta R, et al. BRAFV600 variant allele frequency predicts outcome in metastatic melanoma patients treated with BRAF and MEK inhibitors. J Eur Acad Dermatol Venereol. 2023;37(10):1991\u20138.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"7","key":"7434_CR23","doi-asserted-by":"publisher","first-page":"2173","DOI":"10.1093\/bioinformatics\/btz865","volume":"36","author":"JW Loh","year":"2020","unstructured":"Loh JW, Guccione C, Di Clemente F, Riedlinger G, Ganesan S, Khiabanian H. All-FIT: allele-frequency-based imputation of tumor purity from high-depth sequencing data. Bioinformatics. 2020;36(7):2173\u201380.","journal-title":"Bioinformatics"},{"issue":"1","key":"7434_CR24","doi-asserted-by":"publisher","first-page":"e81","DOI":"10.1002\/cpbi.81","volume":"67","author":"D Prandi","year":"2019","unstructured":"Prandi D, Demichelis F. Ploidy- and Purity-Adjusted Allele-Specific DNA analysis using CLONETv2. Curr Protoc Bioinf. 2019;67(1):e81.","journal-title":"Curr Protoc Bioinf"},{"issue":"1","key":"7434_CR25","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1038\/s42003-023-04764-8","volume":"6","author":"E Revkov","year":"2023","unstructured":"Revkov E, Kulshrestha T, Sung KW, Skanderup AJ. PUREE: accurate pan-cancer tumor purity Estimation from gene expression data. Commun Biol. 2023;6(1):394.","journal-title":"Commun Biol"},{"key":"7434_CR26","doi-asserted-by":"crossref","unstructured":"Haider S, Tyekucheva S, Prandi D, Fox NS, Ahn J, Xu AW, Pantazi A, Park PJ, Laird PW, Sander C, et al. Systematic assessment of tumor purity and its clinical implications. JCO Precis Oncol. 2020;4.","DOI":"10.1200\/PO.20.00016"},{"issue":"8","key":"7434_CR27","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1080\/14737140.2018.1489246","volume":"18","author":"EZ Keung","year":"2018","unstructured":"Keung EZ, Gershenwald JE. The eighth edition American joint committee on cancer (AJCC) melanoma staging system: implications for melanoma treatment and care. Expert Rev Anticancer Ther. 2018;18(8):775\u201384.","journal-title":"Expert Rev Anticancer Ther"},{"issue":"2","key":"7434_CR28","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228\u201347.","journal-title":"Eur J Cancer"},{"key":"7434_CR29","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/1471-2105-12-77","volume":"12","author":"X Robin","year":"2011","unstructured":"Robin X, Turck N, Hainard A, Tiberti N, Lisacek F, Sanchez JC, Muller M. pROC: an open-source package for R and S\u2009+\u2009to analyze and compare ROC curves. BMC Bioinformatics. 2011;12:77.","journal-title":"BMC Bioinformatics"},{"key":"7434_CR30","doi-asserted-by":"crossref","unstructured":"Villanueva RAM, Chen ZJ. ggplot2: elegant graphics for data analysis, 2nd ed. Meas-Interdiscip Res. 2019;17(3):160\u2013167.","DOI":"10.1080\/15366367.2019.1565254"},{"key":"7434_CR31","doi-asserted-by":"publisher","first-page":"3156","DOI":"10.1038\/ncomms4156","volume":"5","author":"KL Kanchi","year":"2014","unstructured":"Kanchi KL, Johnson KJ, Lu C, McLellan MD, Leiserson MD, Wendl MC, Zhang Q, Koboldt DC, Xie M, Kandoth C, et al. Integrated analysis of germline and somatic variants in ovarian cancer. Nat Commun. 2014;5:3156.","journal-title":"Nat Commun"},{"issue":"3","key":"7434_CR32","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1007\/s11864-021-00818-3","volume":"22","author":"T Ito","year":"2021","unstructured":"Ito T, Tanaka Y, Murata M, Kaku-Ito Y, Furue K, Furue M. BRAF heterogeneity in melanoma. Curr Treat Options Oncol. 2021;22(3):20.","journal-title":"Curr Treat Options Oncol"},{"issue":"1","key":"7434_CR33","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1186\/s40478-023-01680-0","volume":"11","author":"M McCord","year":"2023","unstructured":"McCord M, Jamshidi P, Thirunavu V, Santana-Santos L, Vormittag-Nocito E, Dittman D, Parker S, Baczkowski J, Jennings L, Walshon J, et al. Variant allelic frequencies of driver mutations can identify gliomas with potentially false-negative MGMT promoter methylation results. Acta Neuropathol Commun. 2023;11(1):175.","journal-title":"Acta Neuropathol Commun"},{"issue":"2","key":"7434_CR34","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.jmoldx.2017.10.007","volume":"20","author":"SR Yang","year":"2018","unstructured":"Yang SR, Lin CY, Stehr H, Long SR, Kong CS, Berry GJ, Zehnder JL, Kunder CA. Comprehensive genomic profiling of malignant effusions in patients with metastatic lung adenocarcinoma. J Mol Diagn. 2018;20(2):184\u201394.","journal-title":"J Mol Diagn"},{"key":"7434_CR35","doi-asserted-by":"crossref","unstructured":"Zarabi SK, Zhai L, Cheng YW. A challenging correlation between tumor cellularity and somatic variant allele fraction in lung and colorectal cancers-specimens of low tumor percentage should be analyzed with caution. Biomolecules 2024;14(2).","DOI":"10.3390\/biom14020168"},{"issue":"12","key":"7434_CR36","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1016\/j.trecan.2023.08.011","volume":"9","author":"L Boscolo Bielo","year":"2023","unstructured":"Boscolo Bielo L, Trapani D, Repetto M, Crimini E, Valenza C, Belli C, Criscitiello C, Marra A, Subbiah V, Curigliano G. Variant allele frequency: a decision-making tool in precision oncology? Trends Cancer. 2023;9(12):1058\u201368.","journal-title":"Trends Cancer"},{"issue":"1","key":"7434_CR37","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1186\/s12885-019-5990-9","volume":"19","author":"V Doma","year":"2019","unstructured":"Doma V, Karpati S, Raso E, Barbai T, Timar J. Dynamic and unpredictable changes in mutant allele fractions of BRAF and NRAS during visceral progression of cutaneous malignant melanoma. BMC Cancer. 2019;19(1):786.","journal-title":"BMC Cancer"},{"issue":"3","key":"7434_CR38","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1111\/1346-8138.17147","volume":"51","author":"K Namikawa","year":"2024","unstructured":"Namikawa K, Nakano E, Ogata D, Yamazaki N. Long-term survival with systemic therapy in the last decade: can melanoma be cured? J Dermatol. 2024;51(3):343\u201352.","journal-title":"J Dermatol"},{"issue":"2","key":"7434_CR39","first-page":"45","volume":"121","author":"N Eisemann","year":"2024","unstructured":"Eisemann N, Schumann L, Baltus H, Labohm L, Kraywinkel K, Katalinic A. Longer survival from melanoma in Germany. Dtsch Arztebl Int. 2024;121(2):45\u201351.","journal-title":"Dtsch Arztebl Int"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-07434-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-025-07434-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-07434-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T13:26:30Z","timestamp":1765977990000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12967-025-07434-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,17]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["7434"],"URL":"https:\/\/doi.org\/10.1186\/s12967-025-07434-x","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,17]]},"assertion":[{"value":"2 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the local Ethics Committee of Istituto Tumori \u201cGiovanni Paolo II\u201d of Bari (prot. no 1085\/2022 CE) and the Declaration of Helsinki guidelines were followed.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare that they have no competing interests. The authors affiliated to the IRCCS Istituto Tumori \u201cGiovanni Paolo II\u201d, Bari are responsible for the views expressed in this article, which do not necessarily represent the Institute.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was approved by the local Ethics Committee of Istituto Tumori \u201cGiovanni Paolo II\u201d of Bari (prot. no 1085\/2022 CE) and the Declaration of Helsinki guidelines were followed.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1407"}}